Phase 3 data on sunvozertinib for EGFR exon 20 insertions and sacituzumab tirumotecan plus pembrolizumab for PD-L1-positive disease show significant PFS gains over current standards.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/two-phase-3-trials-challenge-chemotherapy-frontline-nsclc-2026a1000iqg?src=rss
Author :
Publish date : 2026-06-04 13:12:00
Copyright for syndicated content belongs to the linked Source.